| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/BJS.10790 |
| P698 | PubMed publication ID | 29341144 |
| P50 | author | Peter Mcanena | Q89668924 |
| P2093 | author name string | M J Kerin | |
| A Lowery | |||
| P2860 | cites work | Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. | Q44946113 |
| miR-206 Inhibits Stemness and Metastasis of Breast Cancer by Targeting MKL1/IL11 Pathway. | Q46142063 | ||
| The level of circulating miRNA-10b and miRNA-373 in detecting lymph node metastasis of breast cancer: potential biomarkers | Q46925242 | ||
| Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group | Q47189470 | ||
| Analytical challenges and technical limitations in assessing circulating miRNAs. | Q50793026 | ||
| Deregulated serum concentrations of circulating cell-free microRNAs miR-17, miR-34a, miR-155, and miR-373 in human breast cancer development and progression. | Q50924410 | ||
| Smoking alters circulating plasma microvesicle pattern and microRNA signatures. | Q51157862 | ||
| A functional polymorphism in the miR-146a gene and age of familial breast/ovarian cancer diagnosis. | Q53318966 | ||
| Tumor microRNA expression profiling identifies circulating microRNAs for early breast cancer detection. | Q53474457 | ||
| Prognostic value of miR-106b expression in breast cancer patients. | Q53628965 | ||
| A serum microRNA signature predicts tumor relapse and survival in triple-negative breast cancer patients. | Q53651538 | ||
| Diagnostic potential of PTEN-targeting miR-214 in the blood of breast cancer patients. | Q53659259 | ||
| Decreased expression of MicroRNA-200 family in human breast cancer is associated with lymph node metastasis. | Q54155851 | ||
| MiR-335 inhibits migration of breast cancer cells through targeting oncoprotein c-Met. | Q55069380 | ||
| Magnetic Resonance Imaging of the Breast Prior to Biopsy | Q57736553 | ||
| MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer | Q21195215 | ||
| Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs | Q24302072 | ||
| Exportin 5 is a RanGTP-dependent dsRNA-binding protein that mediates nuclear export of pre-miRNAs | Q24540256 | ||
| MicroRNA genes are transcribed by RNA polymerase II | Q24562649 | ||
| Genome-wide association study identifies novel breast cancer susceptibility loci | Q24645441 | ||
| Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial | Q27851705 | ||
| Combinatorial microRNA target predictions | Q27860510 | ||
| The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14 | Q27860849 | ||
| Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 | Q27861047 | ||
| MicroRNAs: genomics, biogenesis, mechanism, and function | Q27861070 | ||
| MicroRNA expression profiles classify human cancers | Q28032481 | ||
| A survey of best practices for RNA-seq data analysis | Q28071394 | ||
| Tumour invasion and metastasis initiated by microRNA-10b in breast cancer | Q28131829 | ||
| Regulation of microRNA biogenesis | Q28243976 | ||
| let-7 regulates self renewal and tumorigenicity of breast cancer cells | Q28261263 | ||
| MicroRNA-7, a homeobox D10 target, inhibits p21-activated kinase 1 and regulates its functions | Q28297593 | ||
| Circulating MiR-125b as a marker predicting chemoresistance in breast cancer | Q28482362 | ||
| Cancer statistics, 2016 | Q29547383 | ||
| Endogenous human microRNAs that suppress breast cancer metastasis | Q29617352 | ||
| Breast cancer metastasis: markers and models | Q29618061 | ||
| microRNAs as oncogenes and tumor suppressors | Q29619907 | ||
| Evolution of a research field-a micro (RNA) example. | Q30487729 | ||
| Comparing the MicroRNA spectrum between serum and plasma | Q31080442 | ||
| Comparison of miRNA expression patterns using total RNA extracted from matched samples of formalin-fixed paraffin-embedded (FFPE) cells and snap frozen cells | Q33289523 | ||
| The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis | Q33314551 | ||
| MiR-155 promotes proliferation of human breast cancer MCF-7 cells through targeting tumor protein 53-induced nuclear protein 1 | Q33586516 | ||
| Highlights from the 15th St Gallen International Breast Cancer Conference 15-18 March, 2017, Vienna: tailored treatments for patients with early breast cancer | Q33606741 | ||
| Expression of microRNA-146 suppresses NF-kappaB activity with reduction of metastatic potential in breast cancer cells | Q33609716 | ||
| Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease | Q33769821 | ||
| Oncogenic microRNAs: miR-155, miR-19a, miR-181b, and miR-24 enable monitoring of early breast cancer in serum | Q33824699 | ||
| Systematic analysis of metastasis-associated genes identifies miR-17-5p as a metastatic suppressor of basal-like breast cancer. | Q34049023 | ||
| Circulating miR-19a and miR-205 in serum may predict the sensitivity of luminal A subtype of breast cancer patients to neoadjuvant chemotherapy with epirubicin plus paclitaxel | Q34066078 | ||
| MicroRNA-155 functions as an OncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene | Q34107532 | ||
| Circulating cell-free cancer-testis MAGE-A RNA, BORIS RNA, let-7b and miR-202 in the blood of patients with breast cancer and benign breast diseases | Q34113528 | ||
| Deconstructing the molecular portraits of breast cancer | Q34154147 | ||
| Circulating miR-148b and miR-133a as biomarkers for breast cancer detection | Q34221705 | ||
| A microRNA regulon that mediates endothelial recruitment and metastasis by cancer cells | Q34240754 | ||
| Blood cell origin of circulating microRNAs: a cautionary note for cancer biomarker studies | Q34291952 | ||
| Serum microRNA-155 as a potential biomarker to track disease in breast cancer | Q34447755 | ||
| Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer | Q34613472 | ||
| Dampening enthusiasm for circulating microRNA in breast cancer | Q34614489 | ||
| Plasma processing conditions substantially influence circulating microRNA biomarker levels | Q34769479 | ||
| miR-125b acts as a tumor suppressor in breast tumorigenesis via its novel direct targets ENPEP, CK2-α, CCNJ, and MEGF9. | Q35009302 | ||
| Tumor suppressive function of mir-205 in breast cancer is linked to HMGB3 regulation | Q35009403 | ||
| Plasma microRNA panel for minimally invasive detection of breast cancer | Q35032320 | ||
| Reduced expression levels of let-7c in human breast cancer patients | Q35042277 | ||
| Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice | Q35086711 | ||
| MicroRNA-484 is more highly expressed in serum of early breast cancer patients compared to healthy volunteers | Q35123674 | ||
| MicroRNA-mediated drug resistance in breast cancer | Q35165126 | ||
| Restoration of miR17/20a in solid tumor cells enhances the natural killer cell antitumor activity by targeting Mekk2. | Q35411058 | ||
| Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). | Q35904572 | ||
| Plasma components affect accuracy of circulating cancer-related microRNA quantitation | Q35917691 | ||
| Diagnostic accuracy of mammography, clinical examination, US, and MR imaging in preoperative assessment of breast cancer | Q35919083 | ||
| De novo sequencing of circulating miRNAs identifies novel markers predicting clinical outcome of locally advanced breast cancer | Q35927834 | ||
| Aberrant plasma levels of circulating miR-16, miR-107, miR-130a and miR-146a are associated with lymph node metastasis and receptor status of breast cancer patients | Q35955325 | ||
| Tissue and Serum miRNA Profile in Locally Advanced Breast Cancer (LABC) in Response to Neo-Adjuvant Chemotherapy (NAC) Treatment | Q35985784 | ||
| Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection. | Q36054418 | ||
| Identification of miR-200a as a novel suppressor of connexin 43 in breast cancer cells | Q36185088 | ||
| miR-200c inhibits breast cancer proliferation by targeting KRAS | Q36544271 | ||
| Circulating microRNA-92a and microRNA-21 as novel minimally invasive biomarkers for primary breast cancer | Q36546638 | ||
| Radiation resistance due to high expression of miR-21 and G2/M checkpoint arrest in breast cancer cells | Q36614322 | ||
| Mammography facility characteristics associated with interpretive accuracy of screening mammography | Q36726371 | ||
| Novel combination of serum microRNA for detecting breast cancer in the early stage. | Q36746303 | ||
| Triple-negative breast cancer: therapeutic options | Q36747692 | ||
| microRNA expression profiling on individual breast cancer patients identifies novel panel of circulating microRNA for early detection. | Q36902655 | ||
| Higher expression of circulating miR-182 as a novel biomarker for breast cancer | Q37326193 | ||
| Breast cancer metastasis suppressor 1 up-regulates miR-146, which suppresses breast cancer metastasis | Q37368106 | ||
| MiR-155-mediated loss of C/EBPβ shifts the TGF-β response from growth inhibition to epithelial-mesenchymal transition, invasion and metastasis in breast cancer | Q37501803 | ||
| Identification and validation of oncologic miRNA biomarkers for luminal A-like breast cancer. | Q37538598 | ||
| Decreased expression of key tumour suppressor microRNAs is associated with lymph node metastases in triple negative breast cancer | Q37551941 | ||
| Upregulation of miRNA-155 promotes tumour angiogenesis by targeting VHL and is associated with poor prognosis and triple-negative breast cancer. | Q37586065 | ||
| Triple-negative breast cancer--current status and future directions | Q37630082 | ||
| Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer | Q37655607 | ||
| Identification of a circulating microRNA signature to distinguish recurrence in breast cancer patients | Q37688228 | ||
| Surgical management of the breast: breast conservation therapy and mastectomy | Q38086902 | ||
| Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis | Q38188183 | ||
| The validity of circulating microRNAs in oncology: five years of challenges and contradictions. | Q38198366 | ||
| The emerging role of microRNAs and nutrition in modulating health and disease | Q38230577 | ||
| The role of microRNA in resistance to breast cancer therapy | Q38231981 | ||
| MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1). | Q38303663 | ||
| St. Gallen/Vienna 2017: A Brief Summary of the Consensus Discussion about Escalation and De-Escalation of Primary Breast Cancer Treatment | Q38676979 | ||
| Exosome-encapsulated microRNAs as circulating biomarkers for breast cancer | Q38832499 | ||
| MicroRNA-144 affects radiotherapy sensitivity by promoting proliferation, migration and invasion of breast cancer cells | Q38845583 | ||
| Role of miR-139 as a surrogate marker for tumor aggression in breast cancer | Q39173379 | ||
| miR-206 is down-regulated in breast cancer and inhibits cell proliferation through the up-regulation of cyclinD2. | Q39184534 | ||
| Novel circulating microRNA signature as a potential non-invasive multi-marker test in ER-positive early-stage breast cancer: a case control study. | Q39217323 | ||
| Circulating microRNAs as novel minimally invasive biomarkers for breast cancer | Q39281588 | ||
| MiR-34a inhibits proliferation and migration of breast cancer through down-regulation of Bcl-2 and SIRT1. | Q39343253 | ||
| MicroRNA-30a inhibits cell migration and invasion by downregulating vimentin expression and is a potential prognostic marker in breast cancer | Q39369238 | ||
| miR-125b is methylated and functions as a tumor suppressor by regulating the ETS1 proto-oncogene in human invasive breast cancer. | Q39569218 | ||
| Curcumin down-regulates the multidrug-resistance mdr1b gene by inhibiting the PI3K/Akt/NF kappa B pathway | Q40051078 | ||
| Serum miR-21 and miR-125b as markers predicting neoadjuvant chemotherapy response and prognosis in stage II/III breast cancer | Q40241312 | ||
| A circulating miRNA signature as a diagnostic biomarker for non-invasive early detection of breast cancer | Q40420399 | ||
| Phosphatidylinositol 3'-kinase activation leads to multidrug resistance protein-1 expression and subsequent chemoresistance in advanced prostate cancer cells. | Q40490617 | ||
| Variations in compliance to quality indicators by age for 41,871 breast cancer patients across Europe: a European Society of Breast Cancer Specialists database analysis. | Q41041766 | ||
| Mutation screening of MIR146A/B and BRCA1/2 3'-UTRs in the GENESIS study | Q41691570 | ||
| Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). | Q41875540 | ||
| Identification of circulating microRNA signatures for breast cancer detection | Q43511958 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | breast cancer surgery | Q113001481 |
| P304 | page(s) | e19-e30 | |
| P577 | publication date | 2018-01-01 | |
| P1433 | published in | British Journal of Surgery | Q4970212 |
| P1476 | title | Role of micro-RNAs in breast cancer surgery | |
| P478 | volume | 105 |
Search more.